NEW YORK — French diagnostics firm Theradiag on Monday reported a 12 percent year-over-year increase in preliminary revenues for the first half of the year on growing demand for its theranostics products.
For the first six months of 2021, Theradiag's revenues climbed to €5.5 million ($6.5 million) from €4.9 million in the year-ago period.
Theranostics revenues, which include sales of the company's Tracker line of therapeutic drug monitoring tests, were up nearly 17 percent to €2.8 million from €2.4 million. Theradiag noted that theranostics revenues in the US alone were €500,000, up nearly 34 percent from last year. In vitro diagnostics revenues, meantime, rose 8 percent to €2.7 million from €2.5 million.
At the end of June, Theradiag had €1.4 million in net available cash.
The firm is scheduled to release its full H1 2021 financial results on Sept. 20.